Public Event Detail
Travere Therapeutics Completes $525 Million 0.50% Convertible Notes Offering Led by JPMorgan, Jefferies, Leerink
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Historical observations only. No forecasts, recommendations, buy/sell ratings, or portfolio advice.
2026-05-11JPMJPMorgan ChaseAlpha Vantage Newsm_and_a
Event summary
Travere Therapeutics successfully completed a $525 million registered offering of 0.50% Convertible Senior Notes due 2032, with J.P. Morgan Securities, Jefferies, and Leerink Partners leading the deal. The company plans to use the net proceeds, estimated at $508.5 million, to repurchase a portion of its 2.25% convertible notes due 2029 and for general corporate purposes. Additionally, Travere Therapeutics executed an indenture with U.S. Bank Trust Company to govern the terms of these new 2032 notes.
Attached public signals
Observed outcomes
7d returnPending
30d returnPending
90d returnPending
Relative 90d returnPending